Pernicious anemia has an increased risk for gastric cancer (GC).
It is not established whether pernicious anemia patients need to undergo endoscopic/histological follow-up.
Dr Vannella and colleagues performed a systematic overview of the literature on pernicious anemia and the development of gastric cancer, to estimate the gastric cancer incidence-rate.
According to PRISMA, the team identified studies on pernicious anemia patients reporting the incidence of gastric cancer.
Quality of studies was evaluated using the Newcastle-Ottawa Quality Assessment Scale.
The doctors performed a meta-analysis on annual gastric cancer incidence rates.
The team identified 27 studies that met eligibility criteria.
The research team found that 7 studies were of high, 6 of medium, 10 of low, and 4 of very low quality.
|The calculated pooled gastric cancer incidence-rate was about 0.3% per person-years|
|Alimentary Pharmacology & Therapeutics|
The research team examined that gastric cancer incidence-rates ranged from 0% to 0.2% per person-years in 7 American, from 0% to 0.5% in 2 Asiatic, from 0% to 1% in 11 Northern European studies, and from 0% to 0.9% in 7 studies from other European countries.
The incidence-rates of gastric cancer ranged from 0% to 1.2% per person-years in studies which used gastroscopy, and from 0.1% to 0.9% in those based on International Classification of Disease.
The team found that the calculated pooled gastric cancer incidence-rate was 0.3% per person-years.
The research team examined that meta-analysis showed overall gastric cancer relative risk in pernicious anemia as 6.8.
Dr Vanella's team concluded, "This systematic review shows a pooled gastric cancer incidence-rate in pernicious anemia of about 0.3% per person-years, and an estimated nearly 7-fold relative risk of gastric cancer in pernicious anemia patients."
"Further high quality studies are needed to confirm this higher risk."